TY - JOUR
T1 - Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer
AU - Shibahara, Kotaro
AU - Uchiumi, Takeshi
AU - Kuwano, Michihiko
AU - Maehara, Yoshihiko
AU - Sugio, Kenji
AU - Osaki, Toshihiro
AU - Yasumoto, Kosei
AU - Kohno, Kimitoshi
PY - 2001
Y1 - 2001
N2 - Transcription factor Y-box binding protein 1 (YB-1) that binds to the inverted CCAAT box is involved not only in transcription of various genes but also in cell proliferation and DNA repair. We determined whether localization of YB-1 in either the nucleus or cytoplasm could serve as a prognostic marker for patients with non-small cell lung cancer (NSCLC). In 196 NSCLC patients, expression of YB-1 protein in the nucleus or cytoplasm was immunohistochemically evaluated. Of the 196 tumors examined, 88 (44.9%) were positive for YB-1 expression in the nucleus. Nuclear YB-1 expression significantly correlated with T factor, lymph node metastasis, and stage of the disease. Patients with a nuclear YB-1 tumor had a poorer prognosis than did those with a cytoplasmic YB-1 tumor in all of the NSCLC patients (P=0.0494) and in patients with squamous cell carcinoma (P=0.0313) but not in patients with adenocarcinomas. Nuclear localization of the YB-1 protein may prove to be an important factor of disease progression for patients with NSCLC, in particular, in cases of squamous cell carcinoma.
AB - Transcription factor Y-box binding protein 1 (YB-1) that binds to the inverted CCAAT box is involved not only in transcription of various genes but also in cell proliferation and DNA repair. We determined whether localization of YB-1 in either the nucleus or cytoplasm could serve as a prognostic marker for patients with non-small cell lung cancer (NSCLC). In 196 NSCLC patients, expression of YB-1 protein in the nucleus or cytoplasm was immunohistochemically evaluated. Of the 196 tumors examined, 88 (44.9%) were positive for YB-1 expression in the nucleus. Nuclear YB-1 expression significantly correlated with T factor, lymph node metastasis, and stage of the disease. Patients with a nuclear YB-1 tumor had a poorer prognosis than did those with a cytoplasmic YB-1 tumor in all of the NSCLC patients (P=0.0494) and in patients with squamous cell carcinoma (P=0.0313) but not in patients with adenocarcinomas. Nuclear localization of the YB-1 protein may prove to be an important factor of disease progression for patients with NSCLC, in particular, in cases of squamous cell carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0034796873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034796873&partnerID=8YFLogxK
M3 - Article
C2 - 11595709
AN - SCOPUS:0034796873
SN - 1078-0432
VL - 7
SP - 3151
EP - 3155
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -